A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by either Self/Partner or Healthcare Professional in NEUROENDOCRINOLOGY, vol 94, issue , pp 29-29

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:DiVA.org:liu-73363" > A Randomized, Cross...

1 of 1
Previous record
Next record
To hitlist

A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by either Self/Partner or Healthcare Professional in NEUROENDOCRINOLOGY, vol 94, issue , pp 29-29

Johanson, V (author): Sahlgrens University Hospital

Wilson, B. (author): Odense University Hospital

Abrahamsson, A. (author): Karolinska University Hospital

Jianu, C. (author): St Olav Hospital

Calissendorff, J. (author): Karolinska University Hospital

Wall, Najme (author): Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US

Gronbaek, H. (author): Aarhus University Hospital

Florholmen, J. (author): Department Gastroenterol and Nutr, Tromso

Granberg, D. (author): University Hospital, Uppsala

Ohberg, A. (author): Ipsen AB

show less...

(creator_code:org_t)

Karger, 2011
2011
English.
In: NEUROENDOCRINOLOGY. - : Karger. ; , s. 703-710

Related links:: https://urn.kb.se/re...; show more...; https://doi.org/10.2...; show less...

Conference paper (peer-reviewed)

Abstract Subject headings

Background: Lanreotide Autogel® is supplied in prefilled syringes. Therefore, it is possible for patients with neuroendocrine tumors to use self-/partner-administered injections. The primary objective of this study was to assess the proportion of patients preferring self/partner injections over injections administered by health care professionals, and to describe the impact of self/partner administration on efficacy, safety, and costs. Methods: Of 62 eligible patients, 26 (42%) patients with neuroendocrine tumors treated with a stable dose of lanreotide Autogel 90 mg or 120 mg every 4 weeks agreed to participate in this Phase IV, international, open-label, crossover study, conducted at hospitals in Sweden, Norway, and Denmark. Patients were randomized to two blocks, starting with administration of lanreotide Autogel by either self/partner or a health care professional. Preference for injections administered by self/partner or health care professionals was measured, as well as efficacy, safety, and health care resource utilization (both direct and indirect costs). Results: Of 25 evaluable patients, 22 (88%) preferred self/partner injections, mainly because they experienced increased independence. Based on all patients asked to participate (n = 62), 35% preferred self/partner injections on a regular basis. There was no difference in efficacy or safety between the two administration blocks. Conclusion: Many patients with neuroendocrine tumors prefer self/partner injection of lanreotide Autogel, and are able to self/partner inject without any impact on efficacy or safety. This administration method seems to provide a good alternative for suitable patients to increase patient independence and reduce the number of clinic visits.

Keyword

MEDICINE
MEDICIN

Publication and Content Type

ref (subject category)
kon (subject category)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Johanson, V; Wilson, B.; Abrahamsson, A.; Jianu, C.; Calissendorff, J ...; Wall, Najme; show more...; Gronbaek, H.; Florholmen, J.; Granberg, D.; Ohberg, A.; show less...

Articles in the publication: NEUROENDOCRINOLO ...

By the university: Linköping University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se